Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
| Datum | Name des Inhabers | Gehandelte Aktien | Wertspanne ($) | Transaktionstyp | Preisspanne ($) | Aktien am Meldungsende | % Veränderung |
|---|---|---|---|---|---|---|---|
| 2026-05-02 | Mr. Dalton E. SmartSenior VP of Finance, Principal Accounting Officer & Global Controller | 251,00 | 28,15k | Derivative Exercise and Retained Stock | 112,16 | 9,39k | 2,75% |
| 2026-05-02 | Mr. Dalton E. SmartSenior VP of Finance, Principal Accounting Officer & Global Controller | -132,00 | 0,00 | Derivative Exercise and Sale | 112,16 | 9,39k | - |
| 2026-05-02 | Mr. David R. MaraldoExec. VP & President of Merck Manufacturing Division | 393,00 | 44,08k | Derivative Exercise and Retained Stock | 112,16 | 26,57k | 1,50% |
| 2026-05-02 | Mr. David R. MaraldoExec. VP & President of Merck Manufacturing Division | -159,00 | 0,00 | Derivative Exercise and Sale | 112,16 | 26,57k | - |
| 2026-04-29 | Mr. Chirfi GuindoExec. VP of Strategic Access, Policy & Communications | 998,00 | 109,81k | Derivative Exercise and Retained Stock | 110,03 | 61,67k | 1,64% |
| 2026-04-29 | Mr. Chirfi GuindoExec. VP of Strategic Access, Policy & Communications | -969,00 | 0,00 | Derivative Exercise and Sale | 110,03 | 61,67k | - |
| 2026-04-29 | Mr. Sanat ChattopadhyayInsider | 1,47k | 161,41k | Derivative Exercise and Retained Stock | 110,03 | 200,68k | 0,74% |
| 2026-04-29 | Mr. Sanat ChattopadhyayInsider | -1,13k | 0,00 | Derivative Exercise and Sale | 110,03 | 200,68k | - |
| 2026-04-29 | Mr. Richard R. DeLucaExec. VP & President of Merck Animal Health | 1,28k | 140,51k | Derivative Exercise and Retained Stock | 110,03 | 162,86k | 0,79% |
| 2026-04-29 | Mr. Richard R. DeLucaExec. VP & President of Merck Animal Health | -1,24k | 0,00 | Derivative Exercise and Sale | 110,03 | 162,86k | - |
| 2026-04-29 | Mr. David Michael WilliamsExec. VP and Chief Information & Digital Officer | 698,00 | 76,80k | Derivative Exercise and Retained Stock | 110,03 | 31,72k | 2,25% |
| 2026-04-29 | Mr. David Michael WilliamsExec. VP and Chief Information & Digital Officer | -679,00 | 0,00 | Derivative Exercise and Sale | 110,03 | 31,72k | - |
| 2026-04-29 | Mr. Dalton E. SmartSenior VP of Finance, Principal Accounting Officer & Global Controller | -483,00 | 0,00 | Derivative Exercise and Sale | 110,03 - 110,95 | 9,14k | - |
| 2026-04-29 | Mr. Dalton E. SmartSenior VP of Finance, Principal Accounting Officer & Global Controller | 925,00 | 102,06k | Derivative Exercise and Retained Stock | 110,03 - 110,95 | 9,14k | 11,26% |
| 2026-04-29 | Dr. Dean Y. LiExec. VP & President of Merck Research Laboratories | 2,40k | 263,63k | Derivative Exercise and Retained Stock | 110,03 | 94,43k | 2,60% |
| 2026-04-29 | Dr. Dean Y. LiExec. VP & President of Merck Research Laboratories | -2,33k | 0,00 | Derivative Exercise and Sale | 110,03 | 94,43k | - |
| 2026-04-29 | Ms. Jennifer L. ZacharyExec. VP & General Counsel | 1,50k | 164,71k | Derivative Exercise and Retained Stock | 110,03 | 70,90k | 2,16% |
| 2026-04-29 | Ms. Jennifer L. ZacharyExec. VP & General Counsel | -1,45k | 0,00 | Derivative Exercise and Sale | 110,03 | 70,90k | - |
| 2026-04-29 | Ms. Betty D. LarsonExec. VP & Chief HR Officer | 7,58k | 839,41k | Derivative Exercise and Retained Stock | 110,03 - 110,95 | 13,77k | 122,27% |
| 2026-04-29 | Ms. Betty D. LarsonExec. VP & Chief HR Officer | -5,86k | 0,00 | Derivative Exercise and Sale | 110,03 - 110,95 | 13,77k | - |
| 2026-04-29 | Ms. Caroline A. LitchfieldExec. VP & CFO | 2,00k | 219,73k | Derivative Exercise and Retained Stock | 110,03 | 92,30k | 2,21% |
| 2026-04-29 | Ms. Caroline A. LitchfieldExec. VP & CFO | -1,94k | 0,00 | Derivative Exercise and Sale | 110,03 | 92,30k | - |
| 2026-04-29 | Mr. Robert M. DavisChairman, President & CEO | 6,75k | 742,59k | Derivative Exercise and Retained Stock | 110,03 | 450,35k | 1,52% |
| 2026-04-29 | Mr. Robert M. DavisChairman, President & CEO | -6,55k | 0,00 | Derivative Exercise and Sale | 110,03 | 450,35k | - |
| 2026-04-29 | Mr. Johannes J. OosthuizenExec. VP and President of Oncology & MSD International | 698,00 | 76,80k | Derivative Exercise and Retained Stock | 110,03 | 21,90k | 3,29% |
| 2026-04-29 | Mr. Johannes J. OosthuizenExec. VP and President of Oncology & MSD International | -679,00 | 0,00 | Derivative Exercise and Sale | 110,03 | 21,90k | - |
| 2026-02-12 | Mr. Chirfi GuindoExec. VP of Strategic Access, Policy & Communications | -10,00k | 1,21M | Verkauf | 121,46 | 60,62k | -14,16% |
| 2026-02-10 | Dr. Dean Y. LiExec. VP & President of Merck Research Laboratories | -10,24k | 1,20M | Verkauf | 117,52 | 92,04k | -10,01% |
| 2026-02-09 | Mr. Chirfi GuindoExec. VP of Strategic Access, Policy & Communications | -10,00k | 1,18M | Verkauf | 118,41 | 70,62k | -12,40% |
| 2026-02-09 | Ms. Jennifer L. ZacharyExec. VP & General Counsel | -121,57k | 0,00 | Derivative Exercise and Sale | 119,15 | 68,92k | - |
| 2026-02-06 | Mr. David Michael WilliamsExec. VP and Chief Information & Digital Officer | -5,00k | 221,43k | Derivative Exercise and Sale | 77,62 - 121,91 | 30,84k | - |
| 2026-02-04 | Mr. Dalton E. SmartSenior VP of Finance, Principal Accounting Officer & Global Controller | -4,00k | 230,42k | Derivative Exercise and Sale | 62,07 - 119,68 | 8,21k | - |
| 2026-02-04 | Mr. Dalton E. SmartSenior VP of Finance, Principal Accounting Officer & Global Controller | -2,40k | 287,22k | Verkauf | 119,68 | 8,21k | -22,63% |
| 2026-02-06 | Mr. Johannes J. OosthuizenExec. VP and President of Oncology & MSD International | -15,00k | 1,83M | Verkauf | 121,87 | 21,20k | -41,44% |
| 2026-02-04 | Ms. Caroline A. LitchfieldExec. VP & CFO | -42,00k | 2,79M | Derivative Exercise and Sale | 53,06 - 119,61 | 90,19k | - |
| 2026-02-04 | Dr. Dean Y. LiExec. VP & President of Merck Research Laboratories | -15,09k | 946,35k | Derivative Exercise and Sale | 56,04 - 118,77 | 102,27k | - |
| 2026-02-05 | Mr. Chirfi GuindoExec. VP of Strategic Access, Policy & Communications | -20,00k | 2,44M | Verkauf | 121,88 | 80,62k | -19,88% |
| 2026-02-06 | Mr. Richard R. DeLucaExec. VP & President of Merck Animal Health | -37,69k | 4,56M | Verkauf | 120,92 | 160,17k | -19,05% |
| 2026-02-04 | Mr. Robert M. DavisChairman, President & CEO | -47,43k | 5,60M | Verkauf | 117,38 - 118,35 | 443,60k | -9,66% |
| 2025-11-10 | Ms. Cristal N. DowningInsider | -7,09k | 616,40k | Verkauf | 87,00 | 0,00 | -100,00% |
| 2025-11-03 | Mr. David Michael WilliamsExec. VP and Chief Information & Digital Officer | -8,61k | 720,04k | Verkauf | 83,59 | 24,58k | -25,95% |
| 2025-08-04 | Mr. David Michael WilliamsExec. VP and Chief Information & Digital Officer | 8,69k | 688,79k | Derivative Exercise and Retained Stock | 79,29 | 33,01k | 35,71% |
| 2025-08-04 | Mr. David Michael WilliamsExec. VP and Chief Information & Digital Officer | -8,43k | 0,00 | Derivative Exercise and Sale | 79,29 | 33,01k | - |
| 2025-08-04 | Mr. Chirfi GuindoExec. VP of Strategic Access, Policy & Communications | 18,73k | 1,48M | Derivative Exercise and Retained Stock | 79,29 | 89,29k | 26,54% |
| 2025-08-04 | Mr. Chirfi GuindoExec. VP of Strategic Access, Policy & Communications | -18,18k | 0,00 | Derivative Exercise and Sale | 79,29 | 89,29k | - |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Mit E-Mail registrieren
Haben Sie schon ein Konto? Anmelden
Haben Sie kein Konto? Registrieren
Durch die Registrierung bestätige ich, dass ich die Allgemeinen Geschäftsbedingungen von ADVFN gelesen und verstanden habe und ihnen zustimme und dass ich ein Privatinvestor bin.
Premium
